BACKGROUND: Previous studies have shown that complications and biochemical recurrence rates after radical prostatectomy (RP) vary between different surgeons to a greater extent than might be expected by chance. Data on urinary and erectile outcomes, however, are lacking. OBJECTIVE: In this study, we examined whether between-surgeon variation, known as heterogeneity, exists for urinary and erectile outcomes after RP. DESIGN, SETTING, AND PARTICIPANTS: Our study consisted of 1910 RP patients who were treated by 1 of 11 surgeons between January 1999 and July 2007. INTERVENTION: All patients underwent RP at Memorial Sloan-Kettering Cancer Center. MEASUREMENTS: Patients were evaluated for functional outcome 1 yr after surgery. Multivariable random effects models were used to evaluate the heterogeneity in erectile or urinary outcome between surgeons, after adjustment for case mix (age, prostate-specific antigen, pathologic stage and grade, comorbidities) and year of surgery. RESULTS AND LIMITATIONS: We found significant heterogeneity in functional outcomes after RP (p<0.001 for both urinary and erectile function). Four surgeons had adjusted rates of full continence <75%, whereas three had rates >85%. For erectile function, two surgeons in our series had adjusted rates <20%; another two had rates >45%. We found some evidence suggesting that surgeons' erectile and urinary outcomes were correlated. Contrary to the hypothesis that surgeons "trade off" functional outcomes and cancer control, better rates of functional preservation were associated with lower biochemical recurrence rates. CONCLUSIONS: A patient's likelihood of recovering erectile and urinary function may differ depending on which of two surgeons performs his RP. Functional preservation does not appear to come at the expense of cancer control; rather, both are related to surgical quality.
BACKGROUND: Previous studies have shown that complications and biochemical recurrence rates after radical prostatectomy (RP) vary between different surgeons to a greater extent than might be expected by chance. Data on urinary and erectile outcomes, however, are lacking. OBJECTIVE: In this study, we examined whether between-surgeon variation, known as heterogeneity, exists for urinary and erectile outcomes after RP. DESIGN, SETTING, AND PARTICIPANTS: Our study consisted of 1910 RP patients who were treated by 1 of 11 surgeons between January 1999 and July 2007. INTERVENTION: All patients underwent RP at Memorial Sloan-Kettering Cancer Center. MEASUREMENTS: Patients were evaluated for functional outcome 1 yr after surgery. Multivariable random effects models were used to evaluate the heterogeneity in erectile or urinary outcome between surgeons, after adjustment for case mix (age, prostate-specific antigen, pathologic stage and grade, comorbidities) and year of surgery. RESULTS AND LIMITATIONS: We found significant heterogeneity in functional outcomes after RP (p<0.001 for both urinary and erectile function). Four surgeons had adjusted rates of full continence <75%, whereas three had rates >85%. For erectile function, two surgeons in our series had adjusted rates <20%; another two had rates >45%. We found some evidence suggesting that surgeons' erectile and urinary outcomes were correlated. Contrary to the hypothesis that surgeons "trade off" functional outcomes and cancer control, better rates of functional preservation were associated with lower biochemical recurrence rates. CONCLUSIONS: A patient's likelihood of recovering erectile and urinary function may differ depending on which of two surgeons performs his RP. Functional preservation does not appear to come at the expense of cancer control; rather, both are related to surgical quality.
Authors: Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: Fernando P Secin; Theresa M Koppie; Peter T Scardino; James A Eastham; Manish Patel; Fernando J Bianco; Renaan Tal; John Mulhall; Joseph J Disa; Peter G Cordeiro; Farhang Rabbani Journal: J Urol Date: 2007-02 Impact factor: 7.450
Authors: Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Fernando J Bianco; Andrew J Vickers; Angel M Cronin; Eric A Klein; James A Eastham; J Edson Pontes; Peter T Scardino Journal: J Urol Date: 2010-01-18 Impact factor: 7.450
Authors: Andrew J Vickers; Fernando J Bianco; Angel M Serio; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino Journal: J Natl Cancer Inst Date: 2007-07-24 Impact factor: 13.506
Authors: Andrew J Vickers; Daniel Sjoberg; Ethan Basch; Frank Sculli; Marwan Shouery; Vincent Laudone; Karim Touijer; James Eastham; Peter T Scardino Journal: Eur Urol Date: 2011-11-04 Impact factor: 20.096
Authors: Erika Palagonia; Elio Mazzone; Geert De Naeyer; Frederiek D'Hondt; Justin Collins; Pawel Wisz; Fijs W B Van Leeuwen; Henk Van Der Poel; Peter Schatteman; Alexandre Mottrie; Paolo Dell'Oglio Journal: World J Urol Date: 2019-08-19 Impact factor: 4.226
Authors: Keith J Kowalczyk; Andy C Huang; Nathanael D Hevelone; Stuart R Lipsitz; Hua-yin Yu; John H Lynch; Jim C Hu Journal: World J Urol Date: 2012-11-08 Impact factor: 4.226
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: Stephen B Williams; Blanca E Morales; Linda M Huynh; Kathryn Osann; Douglas W Skarecky; Thomas E Ahlering Journal: J Endourol Date: 2017-10-04 Impact factor: 2.942
Authors: Sigrid V Carlsson; Tiago M de Carvalho; Monique J Roobol; Jonas Hugosson; Anssi Auvinen; Maciej Kwiatkowski; Arnauld Villers; Marco Zappa; Vera Nelen; Alvaro Páez; James A Eastham; Hans Lilja; Harry J de Koning; Andrew J Vickers; Eveline A M Heijnsdijk Journal: Cancer Date: 2016-07-26 Impact factor: 6.860